Coya Therapeutics, Inc. (COYA)
NASDAQ:COYA
Want to see COYA full AI Analyst Report?
Top Page
Coya Therapeutics, Inc.
(NASDAQ:COYA)
Select Model
Select Model
Rating:52Neutral
Price Target:
$5.50
▲(15.06% Upside)
Action:Reiterated
Date:06/23/26
The score is primarily held back by weak financial performance driven by large losses and ongoing cash burn, despite improving revenue and low recent leverage. Technical indicators are moderately supportive and provide the main offset, while valuation remains challenged due to lack of profitability and no dividend support.
Positive Factors
Clinical Progress and Data Accrual
Initiating a blinded extension that extends patient exposure to COYA 302 to 48 weeks materially improves the company’s ability to generate longer-term efficacy and safety data. This reduces clinical uncertainty, strengthens future regulatory submissions, and supports durable evidence generation versus short trials.
Negative Factors
Persistent Negative Cash Flow
Consistent negative operating and free cash flow indicate the business is not self-sustaining and will require external funding until commercialization. Persistent cash burn constrains runway, forces financing timing decisions, and can pressure R&D continuity if capital markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Progress and Data Accrual
Initiating a blinded extension that extends patient exposure to COYA 302 to 48 weeks materially improves the company’s ability to generate longer-term efficacy and safety data. This reduces clinical uncertainty, strengthens future regulatory submissions, and supports durable evidence generation versus short trials.
Read all positive factors
Coya Therapeutics, Inc. (COYA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$124.09M
Dividend YieldN/A
Average Volume (3M)266.35K
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue Growth115.44%
EPS Growth-1.14%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.15
Shares Outstanding23,457,184
10 Day Avg. Volume216,274
30 Day Avg. Volume266,345
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.26
Price to Sales (P/S)12.21
P/FCF Ratio-9.04
Enterprise Value/Market Cap0.33
Enterprise Value/Revenue5.15
Enterprise Value/Gross Profit5.16
Enterprise Value/Ebitda-1.94
Forecast
1Y Price Target
$15.25Price Target Upside219.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.34
Revenue Forecast (FY)$2.71M
Coya Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biolo...
How the Company Makes Money
null...
Coya Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.94M | 7.95M | 3.55M | 6.00M | 0.00 | 0.00 |
| Gross Profit | 7.92M | 7.92M | -8.31M | 500.68K | -4.41M | 0.00 |
| EBITDA | -21.10M | -21.20M | -17.20M | -7.33M | -9.26M | -4.88M |
| Net Income | -21.13M | -21.23M | -14.88M | -7.99M | -12.24M | -4.89M |
Balance Sheet | ||||||
| Total Assets | 53.27M | 49.95M | 44.35M | 41.26M | 8.40M | 4.79M |
| Cash, Cash Equivalents and Short-Term Investments | 50.72M | 46.82M | 38.34M | 32.63M | 5.93M | 4.34M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 12.97M | 0.00 |
| Total Liabilities | 4.30M | 6.92M | 4.77M | 5.63M | 16.79M | 1.15M |
| Stockholders Equity | 48.97M | 43.03M | 39.58M | 35.64M | -8.39M | 3.64M |
Cash Flow | ||||||
| Free Cash Flow | -14.12M | -10.74M | -10.29M | -11.19M | -7.24M | -4.04M |
| Operating Cash Flow | -14.12M | -10.74M | -10.29M | -11.19M | -7.24M | -3.90M |
| Investing Cash Flow | -2.05M | -1.16M | -25.00K | -543.19K | -525.00K | -136.80K |
| Financing Cash Flow | 31.36M | 20.39M | 16.03M | 38.43M | 9.36M | -340.58K |
Coya Therapeutics, Inc. Technical Analysis
Positive
4.78
Price Trends
4.58
Positive
4.57
Positive
5.19
Positive
Market Momentum
0.12
Negative
63.32
Neutral
77.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COYA, the sentiment is Positive. The current price of 4.78 is above the 20-day moving average (MA) of 4.76, above the 50-day MA of 4.58, and below the 200-day MA of 5.19, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 63.32 is Neutral, neither overbought nor oversold. The STOCH value of 77.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COYA.
Coya Therapeutics, Inc. Risk Analysis
Coya Therapeutics, Inc. disclosed 80 risk factors in its most recent earnings report. Coya Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Coya Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $127.96M | 8.19 | 35.58% | ― | 93.50% | ― | |
52 Neutral | $124.09M | -4.60 | -57.26% | ― | 115.44% | -1.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $91.32M | -0.65 | -666.47% | ― | -100.00% | 46.40% | |
45 Neutral | $199.61M | -2.08 | -30.90% | ― | ― | 10.70% | |
45 Neutral | $473.55M | -8.32 | -60.73% | ― | -78.29% | 54.16% | |
42 Neutral | $75.30M | -1.03 | -318.08% | ― | ― | 20.55% |
* Healthcare Sector Average
COYA
Coya Therapeutics, Inc.
5.29
-0.51
-8.79%
INO
Inovio Pharmaceuticals
1.11
-0.82
-42.49%
SPRO
Spero Therapeutics
2.21
-0.72
-24.57%
ANVS
Annovis Bio
1.77
-0.87
-32.95%
NKTX
Nkarta
2.79
1.05
60.34%
STTK
Shattuck Labs
5.24
4.23
418.81%
Coya Therapeutics, Inc. Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Coya Therapeutics Establishes $30 Million ATM Equity Program
Neutral
May 12, 2026
On May 12, 2026, Coya Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC that allows the company to offer and sell up to $30 million of its common stock through at-the-market offerings on the Nasdaq Capital Market. The sha...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance
Coya Therapeutics Updates Q1 Results, COYA 302 Progress
Positive
May 12, 2026
On May 12, 2026, Coya Therapeutics reported first-quarter 2026 results and a corporate update, highlighting U.S. FDA Fast Track Designation granted on March 11, 2026 for its ALS candidate COYA 302 and FDA acceptance of an IND for COYA 302 in front...
Business Operations and StrategyExecutive/Board Changes
Coya Therapeutics Announces Leadership Changes and New Director
Neutral
Apr 2, 2026
Coya Therapeutics, Inc. is a Houston-based, clinical-stage biotechnology company focused on developing proprietary treatments that leverage regulatory T cells to address systemic inflammation and neuroinflammation. Its pipeline includes Treg-enhan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.